Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Cancer is a devastating disease that affects millions of people worldwide. Despite remarkable advancements in cancer research, current cancer treatments are still associated with high toxicity and adverse side effects, leading to a lower quality of life for patients and reduced chances of survival. Granza Bio aims to change this by offering a new and innovative approach to cancer treatment that is both effective and safe.


Granza Bio's therapeutics, "attack particles," are engineered to target cancer cells while leaving healthy cells untouched, thus preventing any unwanted toxicity or side effects. These attack particles have shown remarkable cancer-killing efficacy in brain (glioblastoma), ovarian, lung, and skin cancers. Granza Bio's platform can also be deployed to target a great range of diseases, including autoimmune diseases and infections, making it a versatile and promising tool for treating many different types of illnesses.


The BioEscalator is a perfect place for Granza Bio to continue its mission. The BioEscalator provides state-of-the-art laboratory facilities, access to world-class expertise, and networking opportunities to startups like Granza Bio, enabling them to accelerate their research and development activities.


We are thrilled to welcome Granza Bio to the BioEscalator and are excited about their groundbreaking work in cancer therapeutics.



Ashwin Jainarayanan

Granza Bio, DPhil (PhD) in Interdisciplinary Bioscience - University of Oxford


Ashwin Nandakumar

Ashwin completed his PhD (DPhil) in Oncology at the University of Oxford. After completing his PhD, he began working as a Cancer Research UK postdoctoral researcher at Oxford University and the Institute of Cancer Research (ICR), London. He also brings experience setting up oncology clinical trials and working in oncology startups.